The END Fund
The END Fund focuses on delivering neglected tropical disease (NTD) treatments to those in need by growing and engaging a community of activist-philanthropists, managing high-impact strategic investments, and working in collaboration with government, NGO, pharmaceutical, and academic partners. We aim to take a systems approach to understanding, engaging with, and influencing the broad ecosystem of stakeholders.
The END Fund is the only private philanthropic initiative dedicated to ending the five most common neglected tropical diseases (NTDs) – a group of parasitic and bacterial infectious diseases, such as river blindness and intestinal worms.
By engaging a community of activist-philanthropists and taking a systems approach, we are working in collaboration with governments, NGOs, pharmaceutical, and academic partners to end these diseases in our lifetime.
Since our founding in 2012 through 2020, with our partners, the END Fund has provided over 1 billion treatments for NTDs worth more than $1.3 billion. In 2020 alone, we reached more than 91 million people with more than 133 million NTD treatments, which represents an almost 8-fold increase from 2012.
Geographic Focus26 countries, predominantly in Africa but also Afghanistan, India, Yemen and Guyana.
The END Fund efficiently puts private capital to work, advocating for NTD programs that are innovative, integrated and cost-effective. We facilitate
strong partnerships with the private sector, government partners, and local implementing partners to collaboratively support national disease programs. This is done through a proven implementation model that is tailored to meet the needs of individual countries. The NTDs we work on are: intestinal worms, Schistosomiasis, Onchoceriasis and Lymphatic Filariasis. We have also recently taken on some funding for Visceral Leishmaniasis programmes, following the FCDO cuts.